Company profile
Moleculin Biotech, Inc.
NASDAQ: MBRX · Healthcare · Biotechnology
#1166 of 1,422 Healthcare companies by revenue
EA Score
42DFH 33DQ 57GM —SS 41
v0.1 · 55/100 weight · provisional
↑ disclosure history, balance-sheet leverage · ↓ return on equity, Piotroski F
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$33.6M
Employees
17
as of 2026-08-22
Market cap
$3.2M
as of 2026-08-22
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$0$02025
Net income-$33.6M-$33.6M2025
Operating income-$25.1M-$25.1M2025
Total assets$22.1M$22.1M2025
Liabilities$7.1M$7.1M2025
Equity$15.0M$15.0M2025
Revenue trend
FY2018 – FY2025 · USD
FY18
FY19
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Moleculin Biotech, Inc.’s revenue?
Moleculin Biotech, Inc. booked $0 in FY2025 revenue — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.
Peers · Healthcare
Quest PharmaTech Inc.——nDatalyze Corp.47DElixxer Ltd.14DMedican Enterprises, Inc.——Autonomix Medical, Inc.28DEco-Growth Strategies Inc.——Neighbors
Harris →Key facts
CEOWalter V. Klemp
SectorHealthcare
IndustryBiotechnology
HeadquartersHouston, TX
ExchangeNASDAQ: MBRX
Employees17
IPO date2016-06-02
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.